In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $3.28.
Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion. According to TipRanks, Pantginis has an average return of -19.7% and a 26.95% success rate on recommended stocks.
Currently, the analyst consensus on Armata Pharmaceuticals is a Moderate Buy with an average price target of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
ARMP market cap is currently $118.5M and has a P/E ratio of -3.26.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
